Analysts Set Expectations for IKT Q1 Earnings

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Inhibikase Therapeutics in a report released on Wednesday, February 12th. HC Wainwright analyst E. White anticipates that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.56) EPS.

Separately, Jefferies Financial Group started coverage on Inhibikase Therapeutics in a research note on Friday, November 8th. They issued a “buy” rating and a $8.00 price target on the stock.

Inhibikase Therapeutics Stock Performance

NYSE IKT opened at $2.60 on Monday. The stock’s fifty day moving average is $2.85 and its two-hundred day moving average is $2.20. The firm has a market capitalization of $180.34 million, a P/E ratio of -0.97 and a beta of 1.06. Inhibikase Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $4.20.

Hedge Funds Weigh In On Inhibikase Therapeutics

Large investors have recently modified their holdings of the business. Stifel Financial Corp acquired a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at $43,000. Jefferies Financial Group Inc. acquired a new position in Inhibikase Therapeutics during the 4th quarter worth about $48,000. Alpine Global Management LLC acquired a new position in Inhibikase Therapeutics during the 4th quarter worth about $48,000. Caxton Corp acquired a new position in Inhibikase Therapeutics during the 4th quarter worth about $53,000. Finally, Squarepoint Ops LLC acquired a new position in Inhibikase Therapeutics during the 4th quarter worth about $92,000. Institutional investors and hedge funds own 3.81% of the company’s stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.